AU2010303811B2 - Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent - Google Patents

Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent Download PDF

Info

Publication number
AU2010303811B2
AU2010303811B2 AU2010303811A AU2010303811A AU2010303811B2 AU 2010303811 B2 AU2010303811 B2 AU 2010303811B2 AU 2010303811 A AU2010303811 A AU 2010303811A AU 2010303811 A AU2010303811 A AU 2010303811A AU 2010303811 B2 AU2010303811 B2 AU 2010303811B2
Authority
AU
Australia
Prior art keywords
antimuscarinic agent
agonist
mmol
tert
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010303811A
Other languages
English (en)
Other versions
AU2010303811A1 (en
Inventor
William S. Denney
Scott D. Edmondson
Tara L. Frenkl
Hiroshi Nagabukuro
Mary Struthers Sinharoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2010303811A1 publication Critical patent/AU2010303811A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK SHARP & DOHME CORP.
Application granted granted Critical
Publication of AU2010303811B2 publication Critical patent/AU2010303811B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2010303811A 2009-10-07 2010-09-27 Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent Ceased AU2010303811B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24938609P 2009-10-07 2009-10-07
US61/249,386 2009-10-07
PCT/US2010/050328 WO2011043942A1 (en) 2009-10-07 2010-09-27 Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent

Publications (2)

Publication Number Publication Date
AU2010303811A1 AU2010303811A1 (en) 2012-04-19
AU2010303811B2 true AU2010303811B2 (en) 2013-01-24

Family

ID=43857059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010303811A Ceased AU2010303811B2 (en) 2009-10-07 2010-09-27 Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent

Country Status (15)

Country Link
US (1) US20120202819A1 (cg-RX-API-DMAC7.html)
EP (1) EP2485595A4 (cg-RX-API-DMAC7.html)
JP (1) JP5738871B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120093859A (cg-RX-API-DMAC7.html)
CN (1) CN102638987A (cg-RX-API-DMAC7.html)
AU (1) AU2010303811B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012007829A2 (cg-RX-API-DMAC7.html)
CA (1) CA2774992A1 (cg-RX-API-DMAC7.html)
IL (1) IL218756A0 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN02782A (cg-RX-API-DMAC7.html)
MX (1) MX2012004134A (cg-RX-API-DMAC7.html)
NZ (1) NZ599233A (cg-RX-API-DMAC7.html)
RU (1) RU2012118668A (cg-RX-API-DMAC7.html)
WO (1) WO2011043942A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202520B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011285928B9 (en) * 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EP2706997B1 (en) * 2011-05-10 2019-03-27 TheraVida, Inc. Combinations of solifenacin and pilocarpine for the treatment of overactive bladder
JP6063948B2 (ja) 2011-10-27 2017-01-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ベータ３アゴニストおよび中間体を製造するプロセス
US9809536B2 (en) 2011-10-27 2017-11-07 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
SG11201404776PA (en) * 2012-02-09 2014-09-26 Altherx Inc Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
HUE045260T2 (hu) 2013-03-15 2019-12-30 Merck Sharp & Dohme Eljárás béta 3 antagonisták és köztitermékeik elõállítására
AU2014293141A1 (en) * 2013-07-23 2016-02-18 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
JP2017535567A (ja) 2014-11-20 2017-11-30 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
WO2017015349A1 (en) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination
US12102638B2 (en) 2017-06-06 2024-10-01 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
KR20250095747A (ko) * 2017-06-06 2025-06-26 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 투약
CN111556753A (zh) * 2017-12-21 2020-08-18 杏林制药株式会社 用于夜间尿频的治疗剂
BR112021010856A2 (pt) 2018-12-05 2021-11-16 Urovant Sciences Gmbh Vibegron para o tratamento de sintomas de bexiga hiperativa
CN115850286B (zh) * 2022-12-05 2023-08-22 奥锐特药业(天津)有限公司 一种维贝格龙中间体及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789076B1 (fr) * 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
WO2003024483A1 (fr) * 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1804778A1 (de) * 2004-10-18 2007-07-11 Boehringer Ingelheim International GmbH Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
AU2008233232A1 (en) * 2007-03-29 2008-10-09 Merck Sharp & Dohme Corp. Combination therapy for the treatment-of lower urinary tract symptoms
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OHTAKE, A. et al. Biol. Pharm. Bull. 2007. 30(1): 54-58 *

Also Published As

Publication number Publication date
EP2485595A4 (en) 2014-03-12
IN2012DN02782A (cg-RX-API-DMAC7.html) 2015-09-18
ZA201202520B (en) 2012-12-27
US20120202819A1 (en) 2012-08-09
KR20120093859A (ko) 2012-08-23
BR112012007829A2 (pt) 2015-09-22
JP2013507363A (ja) 2013-03-04
RU2012118668A (ru) 2013-11-20
JP5738871B2 (ja) 2015-06-24
IL218756A0 (en) 2012-06-28
CA2774992A1 (en) 2011-04-14
NZ599233A (en) 2013-04-26
EP2485595A1 (en) 2012-08-15
AU2010303811A1 (en) 2012-04-19
CN102638987A (zh) 2012-08-15
WO2011043942A1 (en) 2011-04-14
MX2012004134A (es) 2012-05-08

Similar Documents

Publication Publication Date Title
AU2010303811B2 (en) Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
JP5432846B2 (ja) β３アドレナリン受容体アゴニストとしてのヒドロキシメチルピロリジン
JP5812500B2 (ja) 新規なβ３アドレナリン作動性受容体アゴニスト
EP3464248A1 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
CA3233408A1 (en) Imidazopyridazine il-17 inhibitor compounds
EP2427194B1 (en) Pyrrolidine-derived beta 3 adrenergic receptor agonists
EP3472149B1 (en) Heterocyclic prolinamide derivatives
AU2011236111B2 (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
AU2011236110B2 (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
HK1147099B (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired